Risk factors for development of ICB-related cutaneous adverse events in general have been published recently based on real-world data and include diagnosis of melanoma or renal cell carcinoma and patients receiving combinatorial ICB with antibodies directed at cytotoxic T-lymphocyte-associated protein 4 (CTLA4) [27]. This evidence concerns the gene CTLA4 and renal cell carcinoma.